Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

6:30 PM - 6:40 PM CT

Welcome and Introductions

6:40 PM - 7:10 PM CT

Module 1: Advances in Antibody-drug Conjugates for the Management of HR+/HER2- mBC

7:10 PM - 7:40 PM CT

Module 2: Applying New Data in ADCs for HER2+ Metastatic Breast Cancer Management

7:40 PM - 8:10 PM CT

Module 3: Integrating Emerging Data for ADCs in the Management of Metastatic Triple Negative Breast Cancer (TNBC)

8:10 PM - 8:30 PM CT

Evidence-Based Summary, Post-session Questions, and Audience Q&A

8:30 PM CT

Adjourn